Cargando…
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
BACKGROUND: Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant breast cance...
Autores principales: | Liu, Bowen, Wang, Tianjiao, Wang, Huawei, Zhang, Lu, Xu, Feifei, Fang, Runping, Li, Leilei, Cai, Xiaoli, Wu, Yue, Zhang, Weiying, Ye, Lihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824486/ https://www.ncbi.nlm.nih.gov/pubmed/29471853 http://dx.doi.org/10.1186/s13045-018-0577-5 |
Ejemplares similares
-
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010) -
Long noncoding RNA HOXB13‐AS1 regulates HOXB13 gene methylation by interacting with EZH2 in glioma
por: Xiong, Yu, et al.
Publicado: (2018) -
HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012) -
HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
por: Jung, C, et al.
Publicado: (2005) -
The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt–PCAF pathway in promotion of esophageal squamous cell carcinoma growth
por: Wu, Yue, et al.
Publicado: (2020)